Page 180 - CW E-Magazine (5-12-2023)
P. 180

CPHI Barcelona 2023


       ing technologies such as the injectables
       segment.  With our new excipients, we
       address the market’s growing trend
       for high-purity ingredients, by solving
       inherent stability  and  bioavailability
       challenges of APIs so that they can travel
       to where needed inside the body and be
       delivered effectively,” said Mr. Michael
       Haspel, Global Head of Segment Perso-
       nal, Home & Health Care at Clariant.
       “We are soon opening our Health Care
       application labs, first in January 2024 in
       Frankfurt Germany at the Clariant Inno-
       vation Centre, and afterwards in New
       Providence, New Jersey, USA, to sup-
       port our customers in tackling their chal-
       lenges with hard-to-solubilise APIs. We
       are all set for collaborative work with
       our customers,” added Mr. Vaios Barlas,
       Global Head of Health Care at Clariant.
       SUSTAINABLE SOLUTIONS

       Bioiberica highlights combined offering of biologi-

       cally-derived APIs and branded ingredients

          At the CPHI Barcelona,  Spanish
       API firm, Bioiberica, showcased its in-
       vestment in scientific research, sustain-
       able development and strategic partner-
       ships. Alongside its API portfolio, the
       company presented the latest research
       for its mobility, digestive  and skin
       health branded ingredients.

          At its booth, Bioiberica exhibited its
       essential  APIs – chondroitin sulphate
       and glucosamine for the symptomatic
       treatment of osteoarthritis, thyroid for
       endocrinology  and  its  flagship  ingre-
       dient, Heparin. It also highlighted its ex-
       pertise in wound care, sharing the scienti-
       fic data set to unlock new co-innovation
       possibilities. The company presented the
       latest  research  supporting  the  efficacy
       of its branded ingredients –  Collavant  oxidase enzyme) for histamine into-  to highlight the substantial strides we’ve
       n2 (native (undenatured) type II colla-  lerance. Mr. Luis Solera, CEO of Bio-  made to strengthen these foundations
       gen),  Mobilee (hyaluronic acid matrix  iberica, commented, “Progression in the  and showcase how we’re supporting
       ingredient) for joint health and mobility,   healthcare space hinges on three key pil-  our customers in addressing some of
       Dermial (hyaluronic acid matrix ingredi-  lars: science, sustainability and strategic  the most pressing challenges facing the
       ent) for skin health and DAOgest (diamine  partnership. CPHI offers us a platform  pharmaceutical industry”.

       180                                                                  Chemical Weekly  December 5, 2023


                                      Contents    Index to Advertisers    Index to Products Advertised
   175   176   177   178   179   180   181   182   183   184   185